China National Pharmaceutical Group, also known as Sinopharm, will step up efforts in innovation to propel high-quality development that is featured by further improvements in industrial, supply and value chains, according to senior company executives on Monday. Liu Jingzhen, Sinopharm chairman, said at a news conference in Beijing that the company will better coordinate industrial development and capital market utilization to complete its layout in the pharmaceutical and healthcare industry and stimulate formation of independently developed new technologies to meet the nation"s need for safeguarding its people's health. The nation's largest healthcare company, Sinopharm ranked 80th on the latest Fortune

State drugmaker provided more than 2.5b doses to 112 regions, world bodies The world's first COVID-19 vaccine developed by State-owned drugmaker Sinopharm marked the first anniversary of its registration and its launch in the market on Thursday. At the same time, the drugmaker has started research and development of vaccines against the latest COVID-19 variant, Omicron, along with research on the variant's structure, the company said in Beijing. Back in June 2020, China and the United Arab Emirates started to conduct phase 3 clinical trials of an inactivated COVID-19 vaccine in the UAE. It was also the first time that